AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO)

Historical Holders from Q1 2014 to Q1 2025

Symbol
AGIO on Nasdaq
CUSIP
00847X104
Type / Class
Equity / Common Stock
Shares outstanding
56.7M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
59.8M
Holdings value
$1.97B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
222
Number of buys
116
Number of sells
-93
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 9.9% $166M 5.67M Dapice Joshua J. Dec 31, 2024
BB BIOTECH AG 6.2% $103M 3.52M BB Biotech AG Dec 31, 2024

Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 143K $4.19M -$371K $29.30 11
2024 Q4 59.8M $1.97B +$43.7M $32.86 222
2024 Q3 57.9M $2.57B -$15.9M $44.43 206
2024 Q2 58.1M $2.51B -$113M $43.12 205
2024 Q1 61.7M $1.8B +$64.5M $29.24 184
2023 Q4 57.8M $1.29B -$15.5M $22.27 166
2023 Q3 57.2M $1.42B -$4.96M $24.75 139
2023 Q2 57.5M $1.63B +$12.2M $28.32 148
2023 Q1 57.3M $1.32B -$9.97M $22.97 159
2022 Q4 57.7M $1.62B +$41.4M $28.08 153
2022 Q3 52.7M $1.49B -$7.97M $28.28 148
2022 Q2 56.9M $1.26B -$31.6M $22.17 137
2022 Q1 57.8M $1.68B +$21.4M $29.11 139
2021 Q4 57.3M $1.88B -$91.3M $32.87 144
2021 Q3 59.7M $2.76B -$247M $46.15 155
2021 Q2 64.8M $3.57B +$49.5M $55.11 177
2021 Q1 64.2M $3.31B +$57.9M $51.64 167
2020 Q4 63.8M $2.77B -$17.9M $43.33 184
2020 Q3 64.5M $2.26B -$115M $35.00 201
2020 Q2 66.6M $3.56B -$65.4M $53.48 200
2020 Q1 68.2M $2.42B +$8.75M $35.48 181
2019 Q4 67.9M $3.24B +$337M $47.75 186
2019 Q3 61.1M $1.98B +$38.7M $32.40 173
2019 Q2 59.9M $2.99B +$322M $49.88 179
2019 Q1 59.6M $4.02B +$162M $67.44 188
2018 Q4 57.4M $2.65B +$50M $46.11 179
2018 Q3 55.7M $4.29B +$92.8M $77.12 199
2018 Q2 54.4M $4.58B -$2.8M $84.23 206
2018 Q1 54.9M $4.48B +$717M $81.78 193
2017 Q4 47M $2.69B +$50.5M $57.17 174
2017 Q3 46.1M $3.07B +$18M $66.75 169
2017 Q2 46.2M $2.37B +$269M $51.45 165
2017 Q1 41M $2.39B +$241M $58.40 154
2016 Q4 38.9M $1.62B +$47.9M $41.73 152
2016 Q3 37.9M $1.99B +$251M $52.82 161
2016 Q2 34.1M $1.42B +$19.6M $41.89 150
2016 Q1 33.8M $1.37B +$17.8M $40.60 146
2015 Q4 33M $2.14B +$93.2M $64.92 138
2015 Q3 31.4M $2.22B +$86.5M $70.59 148
2015 Q2 30M $3.33B +$252M $111.14 159
2015 Q1 27.9M $2.64B -$37M $94.30 149
2014 Q4 27.6M $3.1B +$395M $112.04 144
2014 Q3 24.5M $1.5B +$80.4M $61.35 119
2014 Q2 23.6M $1.08B +$141M $45.82 98
2014 Q1 20.5M $804M +$94M $39.15 73